LOL
One only needs to read the disclosures to see what really occurred:
Conflict of Interest Disclosures: Dr Naggie reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study and grants from Gilead Sciences and AbbVie; personal fees from Pardes Biosciences, Personal Health Insights Inc, and Bristol Myers Squibb/PRA Health Services; and stock options from Vir Biotechnology as well as providing unpaid consultation to Silverback Therapeutics outside the submitted work. Dr Boulware reported receiving grants from the NIH during the conduct of the study. Dr Lindsell reported receiving grants from the National Center for Advancing Translational Sciences (NCATS) during the conduct of the study and grants from the NIH, Centers for Disease Control and Prevention, and Department of Defense to his institution and contracts to his institution for research services from Endpoint Health, bioMerieux, Entegrion Inc, AbbVie, and AstraZeneca outside the submitted work. In addition, Dr Lindsell had a patent for risk stratification in sepsis and septic shock issued to Cincinnati Children’s Hospital Medical Center. Dr Stewart reported receiving grants from the NIH NCATS during the conduct of the study and grants from the NIH outside the submitted work. Dr Gentile reported receiving personal fees from Duke University during the conduct of the study and grants from the NIH outside the submitted work. Dr Collins reported receiving personal fees from Vir Biotechnology during the conduct of the study. Dr Jayaweera reported receiving grants from NCATS during the conduct of the study and grants from Gilead, Pfizer, Janssen, and ViiV and serving as a consultant for Theratechnologies outside the submitted work. Dr Castro reported receiving grants from the NIH, American Lung Association, Patient-Centered Outcomes Research Institute, AstraZeneca, GlaxoSmithKline, Novartis, Pulmatrix, Sanofi, and Shionogi and personal fees from Genentech, Teva, Sanofi, Merck, Novartis, Arrowhead, OM Pharma, Allakos, Amgen, AstraZeneca, GlaxoSmithKline, Regeneron, and Elsevier outside the submitted work. Dr Sulkowski reported receiving personal fees from AbbVie, Gilead, GlaxoSmithKline, Atea Pharmaceuticals, Antios Therapeutics, Precision BioSciences, Viiv, and Virion and grants from Janssen to Johns Hopkins University outside the submitted work. Dr McTigue reported receiving grants to her institution from the NIH during the conduct of the study and research contracts to her institution from Pfizer and Janssen outside the submitted work. Dr Felker reported receiving grants from the NIH during the conduct of the study and grants from Novartis outside the submitted work. Dr Ginde reported receiving grants from the NIH during the conduct of the study and grants from the NIH, Centers for Disease Control and Prevention, Department of Defense, AbbVie (investigator-initiated), and Faron Pharmaceuticals (investigator-initiated) outside the submitted work. Dr Adam reported receiving funding from the US government (funding through Operation Warp Speed) during the conduct of the study. Dr DeLong reported receiving grants from NCATS during the conduct of the study. Dr Hanna reported receiving grants from the US Biomedical Advanced Research and Development Authority during the conduct of the study and personal fees from Merck & Co and AbPro outside the submitted work. Dr Remaly reported receiving grants from NCATS during the conduct of the study. Dr Wilder reported receiving grants from NCATS during the conduct of the study. Dr Wilson reported receiving grants from NCATS during the conduct of the study. Dr Hernandez reported receiving grants from American Regent, Amgen, Boehringer Ingelheim, Merck, Verily, Somologic, and Pfizer, and personal fees from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Cytokinetics, and Merck outside the submitted work. No other disclosures were reported.